GlassScriptPhysician profile
Timothy W Mcdowell
NPI 1972704765
$15,519.42
in general payments reported to CMS, 2019-2025
45 companies · $2,553 in 2025
The $2,553 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,934 · 2022: $2,827 · 2023: $3,401 · 2024: $2,805 · 2025: $2,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,747 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,746.52 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,977.59 | 2021-2025 | Dovato, Apretude, Rukobia |
| Gilead Sciences, INC. | $3,550.09 | 2021-2025 | Yeztugo, Biktarvy |
| Novo Nordisk INC | $785.40 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Theratechnologies INC. | $765.69 | 2021-2025 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $569.61 | 2021-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $546.97 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Pharmaceuticals, INC | $500.26 | 2021-2023 | Xarelto |
| Emd Serono, INC. | $486.14 | 2021-2025 | Serostim |
| Janssen Products, LP | $457.90 | 2022-2023 | Symtuza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.68 | 2021-2024 | Jardiance |
| Amgen INC. | $313.45 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $292.00 | 2021-2025 | |
| Napo Pharmaceuticals INC | $232.52 | 2021-2025 | Mytesi |
| Antares Pharma, INC. | $226.98 | 2021-2023 | Tlando, Xyosted, Nocdurna |
| Takeda Pharmaceuticals U.S.A., INC. | $225.98 | 2021-2024 | Takhzyro, Trintellix |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.